38 stories mentioning GEHCUpdated 5d ago
Every FINWIRES story that references GEHC, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.02, Change: $+0.53, Percent Change: +0.89%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.02, Change: $+0.53, Percent Change: +0.89%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.03, Change: $+0.55, Percent Change: +0.92%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.04, Change: $+0.55, Percent Change: +0.92%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.04, Change: $+0.56, Percent Change: +0.93%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.03, Change: $+0.54, Percent Change: +0.91%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.03, Change: $+0.54, Percent Change: +0.91%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.98, Change: $+0.49, Percent Change: +0.82%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.99, Change: $+0.51, Percent Change: +0.85%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.99, Change: $+0.51, Percent Change: +0.85%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.99, Change: $+0.51, Percent Change: +0.85%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.08, Change: $+0.59, Percent Change: +1.00%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.88, according to analysts polled by FactSet.
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $90.12, according to analysts polled by FactSet.Price: $60.25, Change: $-8.26, Percent Change: -12.05%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GE HealthCare reported mixed Q1 2026 results with revenue of $5.1B, up 7.4% Y/Y (+2.9% organic), but adjusted EBIT margin contracted 150 bps to 13.5% due to operational challenges and inflationary pressures. Adjusted EPS of $0.99 declined modestly from $1.01 in the prior year, impacted by discrete PDx supplier issues, rising memory chip, oil, and freight costs, plus ongoing tariff impacts. Segment performance was mixed, in our view, with Pharmaceutical Diagnostics leading growth at +21.7% reported (+9.7% organic), while Patient Care Solutions declined -6.5% with EBIT margins contracting 500 bps to just 1.4%. Management reduced full-year adjusted EPS guidance to $4.80-$5.00 (from $4.95-$5.15) while maintaining organic revenue growth expectations of 3.0%-4.0%, which we view as achievable. The company expects to offset more than half of inflation impact through pricing and cost mitigation efforts, though margin pressures are expected to persist through 2026, given current challenging market conditions.
Health care stocks were mixed pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.1%.Teva Pharmaceutical Industries (TEVA) shares were up more than 8% after the company posted higher Q1 non-GAAP earnings and net revenue.AstraZeneca (AZN) stock was down more than 1% even after the company reported higher Q1 core earnings and revenue.GE Healthcare Technologies (GEHC) shares were down more than 9% after the company posted a decline in Q1 adjusted earnings, and cut its 2026 adjusted EPS outlook.
GE Healthcare Technologies (GEHC) reported Q1 adjusted earnings Wednesday of $0.99 per diluted share, down from $1.01 a year earlier.Analysts polled by FactSet expected $1.05.Revenue for the quarter ended March 31 was $5.13 billion, compared with $4.78 billion a year earlier.Analysts surveyed by FactSet expected $5.03 billion.For 2026, the company now expects adjusted EPS of $4.80 to $5, compared with its prior guidance of $4.95 to $5.15. Analysts polled by FactSet expect $5.06.Meanwhile, GE Healthcare reiterated its full-year guidance of 3% to 4% organic revenue growth. Analysts polled by FactSet expect $21.71 billion.Shares of the company were down over 6% in Wednesday premarket activity.Price: $64.12, Change: $-4.38, Percent Change: -6.39%
GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $90.41, according to analysts polled by FactSet.Price: $75.36, Change: $+2.16, Percent Change: +2.95%
Showing 21-38 of 38
